Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Edwards Lifesciences reported stronger-than-expected second quarter 2026 financial results, delivering total sales growth of 12.5% year-over-year to $1.74 billion, underpinned by broad-based performance across its structural heart therapy portfolio and geographical regions.</li><li>The company raised its full-year sales guidance to 10% to 11%, reflecting confidence in sustained demand and the strength of multiple growth drivers, while reaffirming its adjusted earnings per share (EPS) guidance within the prior range of $2.95 to $3.05.</li><li>The transcatheter aortic valve replacement (TAVR) segment generated $1.3 billion in sales, increasing 10.5% year-over-year and benefiting from procedural growth, market expansion through new clinical evidence, and the exit of a major competitor in the prior-year quarter.</li></ul>

Edwards Lifesciences reported stronger-than-expected second quarter 2026 financial results, delivering total sales growth of 12.5% year-over-year to $1.74 billion, underpinned by broad-based performance across its structural heart therapy portfolio and geographical regions.The company raised its full-year sales guidance to 10% to 11%, reflecting confidence in sustained demand and the strength of multiple growth drivers, while reaffirming its adjusted earnings per share (EPS) guidance within the prior range of $2.95 to $3.05.The transcatheter aortic valve replacement (TAVR) segment generated $1.3 billion in sales, increasing 10.5% year-over-year and benefiting from procedural growth, market expansion through new clinical evidence, and the exit of a major competitor in the prior-year quarter.

Edwards Lifesciences’ Hidden Growth Engine — TMTT Revenue Just Surged 44.8%!